CureVac Concludes Nasdaq Listing Following BioNTech Acquisition

CureVac NL0015436031

The publicly traded chapter for mRNA specialist CureVac has officially closed. As of today, the company's shares have been delisted from the Nasdaq stock exchange, marking the final step in its transformation into a privately held subsidiary of BioNTech. This move formally concludes the acquisition process that BioNTech initiated last year.

The delisting event encapsulates several key developments. Primarily, BioNTech now holds sole economic ownership of CureVac's business operations. Concurrently, all trading of CureVac stock on the Nasdaq has been terminated. Furthermore, the company will begin the process of fully deregistering from U.S. financial reporting requirements in the coming months.

Final Steps to a Private Structure

The path to delisting was set in motion on January 6. On that date, CureVac announced the completion of a post-offer reorganization linked to BioNTech's successful takeover bid. The company simultaneously notified the Nasdaq exchange, requesting an immediate suspension of trading, and initiated the filing of a Form 25 with the U.S. Securities and Exchange Commission (SEC). This "Notification of Removal from Listing" document is the formal mechanism for withdrawing a stock from exchange listing.

As part of this corporate restructuring, a new entity named CureVac Merger B.V. has replaced the original CureVac company through a statutory merger. The firm no longer has any public shareholders. BioNTech had previously confirmed the completion of the acquisition on December 18, 2025, after approximately 86.75% of CureVac's outstanding shares were tendered. The remaining shares are slated to be transferred via a squeeze-out procedure in January 2026.

This follows the earlier cessation of trading on the Vienna Stock Exchange, where the final trading day occurred on January 7.

Strategic Consolidation in the mRNA Arena

This acquisition closes a significant period for CureVac as an independent pioneer in messenger RNA technology. BioNTech first publicly disclosed its intention to acquire CureVac on June 12, 2025, valuing the target company at an implied equity value of around $1.25 billion.

The transaction has been framed as a merger of two complementary German mRNA enterprises. The strategic goal is to combine research platforms and expertise to fortify their collective position within the global market for mRNA-based therapeutics. Notably, the deal also resolved ongoing patent disputes between the two companies.

Future Operations as a Private Entity

With the Nasdaq delisting now effective, CureVac's shift to a non-listed subsidiary of BioNTech is nearly complete. The next administrative step involves CureVac Merger B.V. planning to submit a Form 15 to the SEC.

Filing this form will terminate the registration of CureVac shares in the United States and suspend the company's reporting obligations under the Securities Exchange Act. A full deregistration is expected to become effective 90 days after the filing is submitted. For former shareholders, this represents the definitive end of the stock's public tradability.

On an operational level, focus will now shift to integrating CureVac's clinical-stage mRNA vaccine projects into BioNTech's broader development pipeline.